Co-occurring hepatitis C, substance use, and psychiatric illness

Treatment issues and developing integrated models of care

Diana L. Sylvestre, Jennifer Loftis, Peter Hauser, Sander Genser, Helen Cesari, Nicolette Borek, Thomas F. Kresina, Leonard Seeff, Henry Francis

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection is transmitted by infection drug use and associated with psychiatric conditions. Patients with drug use or significant psychiatric illness have typically been excluded from HCV treatment trials noting the 1997 National Institutes of Health Consensus Statement on HCV that indicated active drug use and major depressive illness were contraindications to treatment of HCV infection. However, the 2002 NIH Consensus Statement recognized that these patients could be effectively treated for HCV infection and recommended that treatment be considered on a case-by-case basis. Treating HCV infection in these patients is challenging, with drug use relapse possibly leading to psychosocial instability, poor adherence, and HCV reinfection. Interferon therapy may exacerbate preexisting psychiatric symptoms. Co-occurring human immunodeficiency virus or hepatitis B virus provide additional challenges, and access to ancillary medical and psychiatric services may be limited. Patients with co-occurring HCV infection, substance use, and psychiatric illness can complete interferon treatment with careful monitoring and aggressive intervention. Clinicians must integrate early interventions for psychiatric conditions and drug use into their treatment algorithm. Few programs or treatment models are designed to manage co-occurring substance use, psychiatric illness, and HCV infection and therapy. The National Institute on Drug Abuse convened a panel of experts to address the current status and the long-range needs through a 2-day workshop, Co-occurring Hepatitis C, Substance Abuse, and Psychiatric Illness: Addressing the Issues and Developing Integrated Models of Care. This conference report summarizes current data, medical management issues, and strategies discussed.

Original languageEnglish (US)
Pages (from-to)719-734
Number of pages16
JournalJournal of Urban Health
Volume81
Issue number4
DOIs
StatePublished - Dec 2004

Fingerprint

Hepatitis C
Hepacivirus
contagious disease
Psychiatry
illness
Virus Diseases
drug use
Pharmaceutical Preparations
Therapeutics
Interferons
Consensus
National Institute on Drug Abuse (U.S.)
National Institutes of Health (U.S.)
Hepatitis B virus
relapse
Substance-Related Disorders
drug abuse
substance abuse
HIV
Education

Keywords

  • Comorbidities
  • HCV
  • HIV
  • Psychiatric illness
  • Treatment

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Co-occurring hepatitis C, substance use, and psychiatric illness : Treatment issues and developing integrated models of care. / Sylvestre, Diana L.; Loftis, Jennifer; Hauser, Peter; Genser, Sander; Cesari, Helen; Borek, Nicolette; Kresina, Thomas F.; Seeff, Leonard; Francis, Henry.

In: Journal of Urban Health, Vol. 81, No. 4, 12.2004, p. 719-734.

Research output: Contribution to journalArticle

Sylvestre, DL, Loftis, J, Hauser, P, Genser, S, Cesari, H, Borek, N, Kresina, TF, Seeff, L & Francis, H 2004, 'Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care', Journal of Urban Health, vol. 81, no. 4, pp. 719-734. https://doi.org/10.1093/jurban/jth153
Sylvestre, Diana L. ; Loftis, Jennifer ; Hauser, Peter ; Genser, Sander ; Cesari, Helen ; Borek, Nicolette ; Kresina, Thomas F. ; Seeff, Leonard ; Francis, Henry. / Co-occurring hepatitis C, substance use, and psychiatric illness : Treatment issues and developing integrated models of care. In: Journal of Urban Health. 2004 ; Vol. 81, No. 4. pp. 719-734.
@article{2d3df6721da040a2b05a69f3a02afeba,
title = "Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care",
abstract = "Hepatitis C virus (HCV) infection is transmitted by infection drug use and associated with psychiatric conditions. Patients with drug use or significant psychiatric illness have typically been excluded from HCV treatment trials noting the 1997 National Institutes of Health Consensus Statement on HCV that indicated active drug use and major depressive illness were contraindications to treatment of HCV infection. However, the 2002 NIH Consensus Statement recognized that these patients could be effectively treated for HCV infection and recommended that treatment be considered on a case-by-case basis. Treating HCV infection in these patients is challenging, with drug use relapse possibly leading to psychosocial instability, poor adherence, and HCV reinfection. Interferon therapy may exacerbate preexisting psychiatric symptoms. Co-occurring human immunodeficiency virus or hepatitis B virus provide additional challenges, and access to ancillary medical and psychiatric services may be limited. Patients with co-occurring HCV infection, substance use, and psychiatric illness can complete interferon treatment with careful monitoring and aggressive intervention. Clinicians must integrate early interventions for psychiatric conditions and drug use into their treatment algorithm. Few programs or treatment models are designed to manage co-occurring substance use, psychiatric illness, and HCV infection and therapy. The National Institute on Drug Abuse convened a panel of experts to address the current status and the long-range needs through a 2-day workshop, Co-occurring Hepatitis C, Substance Abuse, and Psychiatric Illness: Addressing the Issues and Developing Integrated Models of Care. This conference report summarizes current data, medical management issues, and strategies discussed.",
keywords = "Comorbidities, HCV, HIV, Psychiatric illness, Treatment",
author = "Sylvestre, {Diana L.} and Jennifer Loftis and Peter Hauser and Sander Genser and Helen Cesari and Nicolette Borek and Kresina, {Thomas F.} and Leonard Seeff and Henry Francis",
year = "2004",
month = "12",
doi = "10.1093/jurban/jth153",
language = "English (US)",
volume = "81",
pages = "719--734",
journal = "Journal of Urban Health",
issn = "1099-3460",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Co-occurring hepatitis C, substance use, and psychiatric illness

T2 - Treatment issues and developing integrated models of care

AU - Sylvestre, Diana L.

AU - Loftis, Jennifer

AU - Hauser, Peter

AU - Genser, Sander

AU - Cesari, Helen

AU - Borek, Nicolette

AU - Kresina, Thomas F.

AU - Seeff, Leonard

AU - Francis, Henry

PY - 2004/12

Y1 - 2004/12

N2 - Hepatitis C virus (HCV) infection is transmitted by infection drug use and associated with psychiatric conditions. Patients with drug use or significant psychiatric illness have typically been excluded from HCV treatment trials noting the 1997 National Institutes of Health Consensus Statement on HCV that indicated active drug use and major depressive illness were contraindications to treatment of HCV infection. However, the 2002 NIH Consensus Statement recognized that these patients could be effectively treated for HCV infection and recommended that treatment be considered on a case-by-case basis. Treating HCV infection in these patients is challenging, with drug use relapse possibly leading to psychosocial instability, poor adherence, and HCV reinfection. Interferon therapy may exacerbate preexisting psychiatric symptoms. Co-occurring human immunodeficiency virus or hepatitis B virus provide additional challenges, and access to ancillary medical and psychiatric services may be limited. Patients with co-occurring HCV infection, substance use, and psychiatric illness can complete interferon treatment with careful monitoring and aggressive intervention. Clinicians must integrate early interventions for psychiatric conditions and drug use into their treatment algorithm. Few programs or treatment models are designed to manage co-occurring substance use, psychiatric illness, and HCV infection and therapy. The National Institute on Drug Abuse convened a panel of experts to address the current status and the long-range needs through a 2-day workshop, Co-occurring Hepatitis C, Substance Abuse, and Psychiatric Illness: Addressing the Issues and Developing Integrated Models of Care. This conference report summarizes current data, medical management issues, and strategies discussed.

AB - Hepatitis C virus (HCV) infection is transmitted by infection drug use and associated with psychiatric conditions. Patients with drug use or significant psychiatric illness have typically been excluded from HCV treatment trials noting the 1997 National Institutes of Health Consensus Statement on HCV that indicated active drug use and major depressive illness were contraindications to treatment of HCV infection. However, the 2002 NIH Consensus Statement recognized that these patients could be effectively treated for HCV infection and recommended that treatment be considered on a case-by-case basis. Treating HCV infection in these patients is challenging, with drug use relapse possibly leading to psychosocial instability, poor adherence, and HCV reinfection. Interferon therapy may exacerbate preexisting psychiatric symptoms. Co-occurring human immunodeficiency virus or hepatitis B virus provide additional challenges, and access to ancillary medical and psychiatric services may be limited. Patients with co-occurring HCV infection, substance use, and psychiatric illness can complete interferon treatment with careful monitoring and aggressive intervention. Clinicians must integrate early interventions for psychiatric conditions and drug use into their treatment algorithm. Few programs or treatment models are designed to manage co-occurring substance use, psychiatric illness, and HCV infection and therapy. The National Institute on Drug Abuse convened a panel of experts to address the current status and the long-range needs through a 2-day workshop, Co-occurring Hepatitis C, Substance Abuse, and Psychiatric Illness: Addressing the Issues and Developing Integrated Models of Care. This conference report summarizes current data, medical management issues, and strategies discussed.

KW - Comorbidities

KW - HCV

KW - HIV

KW - Psychiatric illness

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=4644319070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644319070&partnerID=8YFLogxK

U2 - 10.1093/jurban/jth153

DO - 10.1093/jurban/jth153

M3 - Article

VL - 81

SP - 719

EP - 734

JO - Journal of Urban Health

JF - Journal of Urban Health

SN - 1099-3460

IS - 4

ER -